



In re Application of:

KENSIL et al.

Serial No. 07/200,754

Art Unit: 183

Filed: May 31, 1988

Examiner: N. Carson

For: SAPONIN ADJUVANT

: Atty. Dkt.: 0614.0690004

AMENDMENT AND RESPONSE UNDER 37 C.F.R. §1.115

Honorable Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

This responds to the Office Action of May 22, 1989, the period for response to which having been extended to November 22, 1989, by the accompanying Petition for Extension of Time under 37 C.F.R. 1.136.

In the Claims:

Please cancel claims 1-28, without prejudice or disclaimer to the invention thereof.

Please add the following claims:

Substantially pure saponin purified from a crude <u>Quillaja</u> saponaria extract comprising a single predominant peak which comprises 90% or more of the total area of all peaks of a chromatogram, excluding the solvent peak, when analyzed on reverse phase-HPLC on a Vydac C4 column having 5 μ m particle size, 330 Å pore, 4.6 mm ID x 25 cm L in a solvent of 40 mM acetic acid in methanol/water (58/42; v/v) at a flow rate of 1 ml/minute, and wherein said saponin has immune adjuvant activity and is less toxic when used as an adjuvant than said <u>Quillaja</u> saponaria extract.

AIDMAN, STERNE,
SSLER & GOLDSTEIN
ATTORNEYS AT LAW
25 CONNECTICUT AVENUE
VSHINGTON, D. C. 20036
(202) 466-0800